Methotrexate for Nodular Osteoarthritis
Disease-Specific Evidence
- The EULAR guidelines state that management of calcium pyrophosphate deposition with OA should follow evidence-based OA recommendations, with the treatment repertoire remaining "basically the same as that for OA" 1
- The only relevant trial examined methotrexate in chronic CPP crystal inflammatory arthritis, showing clinical response over a mean follow-up of 50.4 months, but this was for inflammatory crystal arthritis, not nodular osteoarthritis 1
Critical Contraindications in Your Patient Population
Renal Impairment
- Stage 3-4 kidney disease requires rigorous toxicity monitoring if methotrexate is considered, as renal impairment is a major risk factor for methotrexate toxicity due to impaired drug clearance 2
Age-Related Risks
- Advanced age (>50 years) increases risk of methotrexate toxicity, including bone marrow suppression, thrombocytopenia, and pneumonitis 2
Specific Concern: Subcutaneous Nodules
- For rheumatoid arthritis patients with subcutaneous nodules, methotrexate is conditionally recommended over alternative DMARDs for moderate-to-high disease activity 3
- However, switching to a non-methotrexate DMARD is conditionally recommended for patients with progressive subcutaneous nodules while on methotrexate, as accelerated nodulosis has been observed 3
Toxicity Profile Relevant to Older Adults
Hematologic Toxicity
- Myelosuppression accounts for the majority (67 out of 164) of methotrexate-associated fatalities 2
- Methotrexate should be stopped immediately if WBC <3,000/mm³, neutrophils <2×10⁹/L, or platelets <100,000/mm³ 2
Pulmonary Toxicity
- Pulmonary fibrosis accounts for 30 out of 164 methotrexate-associated fatalities 2
- Pre-existing lung disease increases risk of methotrexate pneumonitis, though the overall risk is uncertain 3, 4
Gastrointestinal Toxicity
- GI symptoms occur in approximately 30-32% of patients, making this one of the most common adverse effects 2
Mandatory Safety Measures If Methotrexate Is Considered
Folic Acid Supplementation
- All patients on methotrexate must receive folic acid supplementation (1 mg daily or 5 mg weekly, except on the day of methotrexate administration) to reduce gastrointestinal, liver, and hematologic toxicity 2, 4
Monitoring Protocol
- Baseline testing: Complete blood count, renal function (creatinine clearance), liver function tests, chest x-ray 2, 4
- Monitoring frequency: Weeks 2, 4, 8, and 12 after initiation, then at least every 3 months thereafter 2